Feb 9 (Reuters) - ViroPharma Inc (VPHM) said its experimental antiviral compound, maribavir, failed to meet the main goal of a late-stage study in patients who have had bone marrow transplant, hammering its shares down 60 percent to their lowest in more than three years.
Maribavir failed to reduce the incidence of cytomegalovirus (CMV) disease as compared to a dummy drug, the company said.
Cytomegalovirus is a member of the herpes virus family and is a frequent viral illness post transplants. Maribavir was being tested in two separate trials -- in patients receiving stem cell transplants and solid organ transplants. The study also failed to meet the key secondary endpoints. However, the drug was generally well tolerated in the study[who cares?], the company said.
ViroPharma currently has two drugs in the market. Vancocin, an antibiotic, and Cinryze, a treatment for a potentially fatal genetic disease.
Shares of the company fell to a low of $4.89 before paring some losses to trade down $5.71 at $6.50 Monday morning on Nasdaq.‹
(Mar. 9, 2009) — The detailed structure of a protective 'jacket' that surrounds cells of the Clostridium difficile superbug, and which helps the dangerous pathogen stick to human host cells and tissues, is revealed in part in the 1 March issue of Molecular Microbiology. Scientists hope that unravelling the secrets of this protective layer's molecular structure might reveal possible targets for new drugs to treat C. difficile infections.
C. difficile cell. The S-layer is believed to help C. difficile cells colonise the human gut, where they release sickness-causing toxins.
The new research was led by scientists from Imperial College London, funded by the European Union Seventh Framework Programme and the Medical Research Council. They used X-ray crystallography techniques to produce the first ever high-resolution images of the structure of LMW-SLP, one of the two proteins that make up C. difficile’s S-layer. The team also produced lower resolution images of the two S-layer proteins linked together to form the 'building block' which makes up the layer over all.
Understanding exactly how the S-layer is formed, and how it works, could reveal new ways of fighting C. difficile infections, because without the S-layer, the pathogen cells cannot function, and die. The team behind the new study say that the long term aim is to use this structural knowledge to design a drug that will target the S-layer, leading to cell death, and the defeat of infection.
In addition, the research team behind today's study say that understanding the S-layer could be the key to developing a preventative vaccine for C. difficile. This is because the protein outer-shell of the pathogen is 'seen' and recognised as dangerous by the human immune system, triggering an immune response. This means that in the future, if the structure of these proteins is fully understood, they could one day be administered as a vaccine to pre-prepare the body to fight infection.
Professor Neil Fairweather, from Imperial College London's Department of Life Sciences, explains that his group's findings are an important in developing new treatments for C. difficile infections:
"This is the first time anyone has gained detailed information about the molecular structure of C. difficile's protective 'jacket', because analysing the two protein components is painstakingly difficult work. We're confident that continuing this work to better understand the formation of this protective coat and its exact function will reveal new targets for effective drugs to beat this dangerous pathogen, and could even lead to an effective vaccine."
The team's next steps will be to produce a high resolution image of the structure of the whole S-layer, and to further analyse the areas where the two proteins link together in the layer.
Clostridium difficile is a bacterial pathogen that is present naturally in the gut of about three percent of adults, and 66 percent of children. It does not cause problems in healthy people, but antibiotics used to treat other health problems can sweep away the 'good' bacteria in the gut, leaving C. difficile free to multiply dramatically causing severe diarrhoea and inflammation.
Because C. difficile is usually caused by taking antibiotics, most cases happen in hospitals or care homes. C. difficile is naturally resistant to lots of antibiotic treatments, and can recur once contracted. There are now more cases of C. difficile than MRSA in the UK, and in 2007 over 8000 deaths were associated with C. difficile.
Journal reference:
Fagan et al. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Molecular Microbiology, 2009; 71 (5): 1308 DOI: 10.1111/j.1365-2958.2009.06603.x
News 
Market Data 
Discover 
AI
